AWARD NUMBER: W81XWH-15-2-0031

TITLE: Novel Strategies to Improve Immunomodulation and Non-Invasive Clinical Monitoring in VCA

PRINCIPAL INVESTIGATOR: Bohdan Pomahac, MD

CONTRACTING ORGANIZATION: Brigham and Women’s Hospital
                                Boston, MA 02115

REPORT DATE: August 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                         Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
Novel Strategies to Improve Immunomodulation and Non-Invasive Clinical Monitoring in VCA

Bohdan Pomahac, MD
E-Mail: bpomahac@partners.org

Brigham and Women’s Hospital
75 Francis St
Boston MA 02115

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA.(2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM).

We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned.will
1. Introduction

Many individuals lose parts of their faces, their limbs or their abdomen in traumatic incidents such as active combat, burns, gunshot wounds, violent attacks, and motor vehicle accidents, amongst others. People with these types of traumatic injuries have decreased quality of life, and are often disabled. Although they may receive the best of the available conventional reconstruction therapies, they continue to suffer from chronic pain, psychological distress, social isolation, and limitations in their ability to perform daily activities such as bathing, dressing, ambulating, and eating without substantial help. “Vascularized composite allotransplantation”, or “VCA” for short, is a new promising therapy for these types of patients. Face transplants, hand transplants and abdominal wall transplants are examples of types of VCA.

The most significant disadvantage of VCA is that patients who receive this therapy must take immunosuppressive drugs for the rest of their lives in order to prevent their bodies from rejecting the transplant. Immunosuppressive drugs pose significant health risks. As VCA is not a life-saving therapy, the risks of immunosuppressive drugs are given much more consideration than in the case of, for example, a heart transplant. Therefore, many people who would benefit from VCA end up not receiving the therapy due to concerns about immunosuppression. We have developed a novel, safe treatment that may enable patients who receive VCA to drastically reduce or even completely eliminate immunosuppressive drugs in the months after transplantation. The objective of this study is to test this novel treatment in 5 patients who will receive VCA. At least 3 months after their VCA operations, our patients will receive our novel treatment which is based on low doses of “interleukin-2” or “IL-2” for short, over a period of 3-4 months. After receiving IL-2 treatment, we will try to minimize or possibly stop immunosuppressive drugs in our patients. If, however, we see signs of rejection, we give standard immune suppression back, which stops rejection successfully in the vast majority of VCA patients. We will follow the progress of our patients for 24 months thereafter. Using state of the art molecular, cellular and imaging technologies, we monitor the subjects’ immune status to identify patients who can safely minimize immune suppression and those who are likely to suffer rejection.

VCA will give many patients the opportunity to improve their quality of life and regain social participation and independence. Our study is carefully designed to thoroughly inform the patients about risks and benefits of participation, to minimize the incidence of complications, and if it is not possible to avoid them, have a safe treatment plan.
2. Key Words:
Vascularized composite allotransplantation, immune modulation, immune tolerance, IL-2

3. Accomplishments.
Our main accomplishment this year was to elucidate the complex path to HRPO regulatory approval in order to proceed with recruitment of subjects for this study. This study involves 4 of our currently active and approved IRB protocols. We have submitted these protocols along with the entire HRPO package, and are currently going through clarification questions/answers with our HRPO contact.
In the meantime, we have:
- Maintained IRB approval of all involved protocols up-to-date and through continuing reviews
- Reported to the FDA and maintained IND approval for use of IL-2 in this patient population
- In a study funded by AFIRM II, which administers IL-2 to patients who ALREADY had VCA interventions (i.e. retrospective trial), we have learned important lessons and made important scientific findings based on the recruitment and trial of one individual subject. These lessons/findings are expected to result in improvements to the study protocol that will need to be approved by the IRB, FDA and HRPO.
In addition, we have kept up with our monthly teleconference calls with the sponsor, as well as maintained up to date reporting requirements.

4. Impact
Active combat is inflicting multiple devastating injuries to unprotected body areas such as the face and limbs with alarming incidence, and resulting in limb amputation, facial disfigurement, and loss of abdominal wall. Conventional reconstructive surgery is limited in its ability to restore form and function after these injuries. Disability with associated long-term medical care and disability benefit costs is common. Considering the high incidence and devastating consequences of these complex injuries to American Service members, there is a clear need to improve their treatment outcomes. Vascularized composite allotransplants provide a mean to functionally and cosmetically restore these tissues; however, at the cost of lifelong immunosuppression. If successful, these studies will facilitate induction of immunologic tolerance to the transplanted tissues thus improving the rate of return to duty, deployment and function of American service members and veterans recovering.
from combat-related limb loss, with associated improvements in quality of life, mental health, social participation and the American economy.

5. Changes/Problems
Our most significant roadblock this year has been to elucidate a path to HRPO approval of this study, mainly because the study comprises several different IRB protocols and the path to subject enrollment involves enrollment in various different trials. We have addressed this issue now, however and HRPO submission is in place.

6. Products
Nothing to report at this time.

7. Publications, Abstracts and Presentations
We presented at the Department of Defense’s meeting at Fort Detrick on April 15th, 2016.

8. Inventions, Patents and Licenses
Nothing to report at this time.

9. Reportable Outcomes
Nothing to report at this time.

10. Other Achievements
Nothing to report at this time.

11. Participant and other collaborating organizations
Our collaborations with the Massachusetts Institute of Technology and the Beth Israel Medical Deaconness Center remain in place and active; we have obtained ceded review from their institutional IRBs so that their contribution to our studies remains under oversight by the Partners Human Research Committee.
12. **Special Reporting Requirements**

None.

13. **Appendices**

None.